Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity
Bibliographic record
Abstract
■ Lebrikizumab is a monoclonal antibody that binds with high affinity and slow dissociation rate to IL-13, thereby blocking the downstream effects of IL-13 with high potency 1 ■ Lebrikizumab has demonstrated clinical benefit in patients with moderate-to-severe AD in the randomized, placebo-controlled, Phase 3 ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967) trials 2,3 OBJECTIVE ■ To assess efficacy of lebrikizumab in the ADvocate1 and ADvocate2 trials within subgroups of patients with moderate (IGA=3) vs. severe (IGA=4) AD at baseline Statistical results of the primary and major secondary endpoints for ADvocate1 and ADvocate2 were confirmed through replicate statistical programming, validation, and quality reviews 2,3 CONCLUSION ■ Regardless of baseline disease severity, lebrikizumab 250 mg Q2W demonstrated consistent and robust efficacy on skin and itch in patients with moderate or severe AD at Week 16 Key Eligibility Criteria ■ Adults (≥18 years of age) and adolescents (12 to <18 years of age, weighing ≥40 kg) ■ Diagnosis of AD, as defined by the American Academy of Dermatology Consensus Criteria, for ≥1 year before screening ■ Moderate-to-severe AD, defined as having all the following at the baseline visit: -EASI ≥16 -IGA ≥3 -BSA involvement ≥10% ■ Candidate for systemic therapy Outcome ■ Treatment difference for lebrikizumab vs. placebo between the baseline AD subgroups, moderate AD (IGA=3) vs. severe AD (IGA=4), was calculated at Week 16 for:-IGA 0/1 with ≥2-point improvement -EASI 75 a The Pruritus NRS is a patient-reported, single-item, 11-point scale that is used daily by participants to rate their worst itch severity over the past 24 hours (0 indicating "no itch"; 10 indicating "worst itch imaginable" 4 ); b Based on patients with baseline Pruritus NRS ≥4
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.003 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.003 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".